HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
Conclusion:
Our finding that IBC cells are sensitive to HDAC6 inhibition provides a foundation to rapidly develop novel, efficient, and well-tolerated targeted therapy strategies for IBC patients.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Preeti PutchaJiyang YuRuth Rodriguez-BarruecoLaura Saucedo-CuevasPatricia VillagrasaEva Murga-PenasSteven QuayleMin YangVeronica CastroDavid Llobet-NavasDaniel BirnbaumPascal FinettiWendy WoodwardFrançois BertucciMary AlpaughAndrea CalifanoJose Silva Source Type: research
More News: Addiction | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Study